Our round-up of the major patent issues affecting pharma and biotech that emerged on the legal, market and policy fronts last month
Consolidation in the chip industry continues as the deal brings together two players with plenty of experience in the secondary market
The high invalidation rate for life science patents in China has created a headache for drug companies and a money-making opportunity for enterprising individuals
A selection of recently reported facts and figures.
Portuguese national says he has sold his house to hire an attorney to go after the Chinese company over alleged IP theft – a huge leap of faith given US assertion realities
IAM's annual benchmarking survey is designed to identify the key concerns of senior decision makers in areas such as deal-making, valuation, patent office performance, top litigation venues and policy
Dan McCurdy (left) and Mattia Fogliacco (right) open up about the ground-breaking patent agreement their two firms secured in January - and explain why it is potentially so important
As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies
Agreement covers a total of 700 patents and is a big win for the CEOs of both firms - Mattia Fogliacco (left) and Dan McCurdy (right)
Retrial ordered in Huawei v InterDigital; Apple representatives threatened with detention in continuing injunction flap; national IP appeals court opens doors and much more from the Middle Kingdom
“Largest open market patent deal in telecoms since Nortel” will reveal extent of secondary market’s slow recovery
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.
TCL v Ericsson and Unwired Planet v Huawei send two very different messages to auto companies being approached by patent pools such as Avanci to take SEP licences, says Unified Patents' chief IP counsel Jonathan Stroud
Sources tell IAM MPEG-LA has secured an AVC/H.264 licence with Xiaomi.